Orig3n Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 28
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $26.2M
Latest Deal Amount
  • Investors
  • 13

Orig3n General Information

Description

Provider of DNA test kits intended to treat rare genetically inherited diseases. The company's DNA tests leverage biological science and technology to provide people with access to information about their genes to make proactive and personalized choices that may impact their well-being, enabling users to be well-informed about their bodies and make informed decisions.

Contact Information

Website
www.orig3n.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Monitoring Equipment
Information Services (B2C)
Primary Office
  • 27 Drydock Avenue
  • 3rd Floor
  • Boston, MA 02210
  • United States
+1 (800) 000-0000

Orig3n Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Orig3n Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 09-Sep-2020 $26.2M 00000 Completed Generating Revenue
6. Debt - PPP 15-Apr-2020 00000 000.00 Completed Generating Revenue
5. Early Stage VC 08-Nov-2019 00000 000.00 Completed Generating Revenue
4. Early Stage VC (Series B) 11-Jul-2018 0000 000.00 00000 Completed Generating Revenue
3. Early Stage VC (Series A2) 27-Jun-2017 0000 000.00 0000 Completed Generating Revenue
2. Early Stage VC (Series A) 16-Dec-2015 $12.5M $15.6M 0000 Completed Generating Revenue
1. Early Stage VC (Series 1) 05-Feb-2015 $3.14M $3.14M 00.000 Completed Generating Revenue
To view Orig3n’s complete valuation and funding history, request access »

Orig3n Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series A2 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series A 11,372,211 $0.000100 6% $1.1 $1.1 1x $1.1 13.49%
Series 1 7,498,225 $0.000100 6% $0.42 $0.42 1x $0.42 8.89%
To view Orig3n’s complete cap table history, request access »

Orig3n Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Provider of DNA test kits intended to treat rare genetically inherited diseases. The company's DNA tests leverage biolog
Biotechnology
Boston, MA
28 As of 2021
00000
0000000000 0 00000

0000000

ulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mo
0000 000000000
San Mateo, CA
0 As of 0000
00.000
00.00 0000-00-00
00000000000 00.000

000000

idunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco l
0000 000000000
Cambridge, MA
0 As of 0000
00.00
00000000000 00.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Orig3n Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NuMedii Venture Capital-Backed San Mateo, CA 0 00.000 00000000000 00.000
000000 Venture Capital-Backed Cambridge, MA 0 00.00 00000000000 00.00
00000000 Venture Capital-Backed San Francisco, CA 00 00000 00000000000 00000
0000000 Venture Capital-Backed Toronto, Canada 00 000.00 00000 000.00
00000 00000000 Venture Capital-Backed San Francisco, CA 00 000.00 00000000000 000.00
You’re viewing 5 of 8 competitors. Get the full list »

Orig3n Executive Team (7)

Name Title Board Seat Contact Info
Robin Smith Co-Founder, Chief Executive Officer & Board Member
Kate Blanchard Co-Founder & Chief Operating Officer
Michael Fang MD Chief Medical Officer
You’re viewing 3 of 7 executive team members. Get the full list »

Orig3n Board Members (7)

Name Representing Role Since
Angela Ruggiero Self Board Member 000 0000
Byron Smith Mountain Group Partners Board Member 000 0000
Clay Thorp Hatteras Venture Partners Board Member 000 0000
Dylan Dai Orig3n Board Member 000 0000
Elona Baum DEFTA Partners Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Orig3n Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Orig3n Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Sekhmet Ventures Venture Capital Minority 000 0000 000000 0
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
Haitong International Securities Group Hedge Fund Minority 000 0000 000000 0
MMIC Investment Venture Capital Minority 000 0000 000000 0
Vectr Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »

Orig3n Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 000000000 01-Aug-2020 000000000000000000 Diagnostic Equipment
Interleukin Genetics 22-Nov-2017 Merger/Acquisition Diagnostic Equipment
To view Orig3n’s complete acquisitions history, request access »

Orig3n Subsidiaries (1)

Company Name Industry Location Founded
00000000 000000000 Diagnostic Equipment Redwood City, CA 0000
To view Orig3n’s complete subsidiaries history, request access »